X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PANACEA BIOTECH ALEMBIC PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 25.1 -17.3 - View Chart
P/BV x 5.1 2.0 247.2% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ALEMBIC PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
PANACEA BIOTECH
Mar-14
ALEMBIC PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs645149 433.8%   
Low Rs47082 570.8%   
Sales per share (Unadj.) Rs166.184.1 197.4%  
Earnings per share (Unadj.) Rs21.9-18.3 -119.6%  
Cash flow per share (Unadj.) Rs27.5-6.7 -410.4%  
Dividends per share (Unadj.) Rs4.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs117.883.7 140.7%  
Shares outstanding (eoy) m188.5261.25 307.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 244.5%   
Avg P/E ratio x25.5-6.3 -403.5%  
P/CF ratio (eoy) x20.3-17.2 -117.6%  
Price / Book Value ratio x4.71.4 343.1%  
Dividend payout %18.30-   
Avg Mkt Cap Rs m105,0907,074 1,485.5%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m6,2281,449 429.8%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m31,3085,154 607.5%  
Other income Rs m70100 70.4%   
Total revenues Rs m31,3785,254 597.3%   
Gross profit Rs m6,431-766 -839.2%  
Depreciation Rs m1,055711 148.3%   
Interest Rs m341,503 2.3%   
Profit before tax Rs m5,413-2,881 -187.9%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-81-6 1,419.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m1,20417 7,163.7%   
Profit after tax Rs m4,128-1,121 -368.2%  
Gross profit margin %20.5-14.9 -138.1%  
Effective tax rate %22.2-0.6 -3,812.4%   
Net profit margin %13.2-21.8 -60.6%  
BALANCE SHEET DATA
Current assets Rs m18,2473,810 478.9%   
Current liabilities Rs m11,2358,365 134.3%   
Net working cap to sales %22.4-88.4 -25.3%  
Current ratio x1.60.5 356.6%  
Inventory Days Days86156 55.0%  
Debtors Days Days6167 91.3%  
Net fixed assets Rs m20,03514,480 138.4%   
Share capital Rs m37761 615.0%   
"Free" reserves Rs m21,824903 2,416.6%   
Net worth Rs m22,2015,127 433.0%   
Long term debt Rs m5,0005,832 85.7%   
Total assets Rs m39,41119,433 202.8%  
Interest coverage x160.2-0.9 -17,478.9%   
Debt to equity ratio x0.21.1 19.8%  
Sales to assets ratio x0.80.3 299.6%   
Return on assets %10.62.0 537.7%  
Return on equity %18.6-21.9 -85.0%  
Return on capital %19.73.6 542.5%  
Exports to sales %46.424.5 189.3%   
Imports to sales %10.510.2 103.1%   
Exports (fob) Rs m14,5351,264 1,150.1%   
Imports (cif) Rs m3,288525 626.6%   
Fx inflow Rs m14,7221,539 956.4%   
Fx outflow Rs m7,026942 745.8%   
Net fx Rs m7,696597 1,288.6%   
CASH FLOW
From Operations Rs m3,124599 521.4%  
From Investments Rs m-8,844-438 2,019.6%  
From Financial Activity Rs m5,026-303 -1,661.0%  
Net Cashflow Rs m-693-141 490.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 0.6 483.3%  
FIIs % 9.1 1.3 700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 23.6 58.9%  
Shareholders   49,328 10,259 480.8%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   ALKEM LABORATORIES  STRIDES SHASUN LTD  TTK HEALTHCARE  TORRENT PHARMA  DISHMAN PHARMA  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 132 Points Higher; IT and Healthcare Stocks Witness Buying(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed buying interest during the closing hours and ended the day in green.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 7.1% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 7.1% YoY). Sales on the other hand came in at Rs 9 bn (up 15.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Oct 15, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - NOVARTIS COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS